JP2021517457A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2021517457A5 JP2021517457A5 JP2020548645A JP2020548645A JP2021517457A5 JP 2021517457 A5 JP2021517457 A5 JP 2021517457A5 JP 2020548645 A JP2020548645 A JP 2020548645A JP 2020548645 A JP2020548645 A JP 2020548645A JP 2021517457 A5 JP2021517457 A5 JP 2021517457A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- region
- amino acid
- heavy chain
- light chain
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2022143428A JP7447208B2 (ja) | 2018-03-12 | 2022-09-09 | 抗体 |
| JP2024027970A JP7791229B2 (ja) | 2018-03-12 | 2024-02-28 | 抗体 |
| JP2025245068A JP2026041981A (ja) | 2018-03-12 | 2025-12-11 | 抗体 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18161293.8 | 2018-03-12 | ||
| EP18161293 | 2018-03-12 | ||
| EP18175347 | 2018-05-31 | ||
| EP18175347.6 | 2018-05-31 | ||
| PCT/EP2019/056197 WO2019175198A2 (en) | 2018-03-12 | 2019-03-12 | Antibodies |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022143428A Division JP7447208B2 (ja) | 2018-03-12 | 2022-09-09 | 抗体 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021517457A JP2021517457A (ja) | 2021-07-26 |
| JP2021517457A5 true JP2021517457A5 (cg-RX-API-DMAC7.html) | 2021-10-07 |
| JP7209008B2 JP7209008B2 (ja) | 2023-01-19 |
Family
ID=65729373
Family Applications (4)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020548645A Active JP7209008B2 (ja) | 2018-03-12 | 2019-03-12 | 抗体 |
| JP2022143428A Active JP7447208B2 (ja) | 2018-03-12 | 2022-09-09 | 抗体 |
| JP2024027970A Active JP7791229B2 (ja) | 2018-03-12 | 2024-02-28 | 抗体 |
| JP2025245068A Pending JP2026041981A (ja) | 2018-03-12 | 2025-12-11 | 抗体 |
Family Applications After (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022143428A Active JP7447208B2 (ja) | 2018-03-12 | 2022-09-09 | 抗体 |
| JP2024027970A Active JP7791229B2 (ja) | 2018-03-12 | 2024-02-28 | 抗体 |
| JP2025245068A Pending JP2026041981A (ja) | 2018-03-12 | 2025-12-11 | 抗体 |
Country Status (20)
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102813816B1 (ko) * | 2013-07-05 | 2025-05-29 | 젠맵 에이/에스 | 인간화 또는 키메라 cd3 항체 |
| FI3322727T3 (fi) | 2015-07-15 | 2026-03-17 | Genmab As | Humanisoituja tai kimeerisiä CD3-vasta-aineita |
| IL319047A (en) | 2015-08-28 | 2025-04-01 | Amunix Operating Inc | Chimeric polypeptide composition and methods for its preparation and use |
| MA52152A (fr) | 2018-03-12 | 2021-01-20 | Genmab As | Anticorps |
| US12674001B2 (en) | 2019-09-12 | 2026-07-07 | Genmab A/S | Method of treating cancer by administering an antibody which binds to 5T4 |
| EP4210752A4 (en) * | 2020-09-11 | 2025-09-24 | Actinium Pharmaceuticals Inc | Trophoblastic Glycoprotein Radiation Immunotherapy for the Treatment of Solid Cancers |
| CA3202891A1 (en) | 2021-01-28 | 2022-08-04 | Kara Olson | Compositions and methods for treating cytokine release syndrome |
| MX2023013018A (es) * | 2021-05-04 | 2024-01-18 | Immunorizon Ltd | Anticuerpos anti-5t4 y usos de estos. |
| WO2023107954A1 (en) * | 2021-12-08 | 2023-06-15 | Dragonfly Therapeutics, Inc. | Antibodies targeting 5t4 and uses thereof |
| AU2023254191A1 (en) | 2022-04-11 | 2024-10-17 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for universal tumor cell killing |
| US20260167739A1 (en) * | 2022-11-08 | 2026-06-18 | Phanes Therapeutics, Inc. | Anti-5t4 antibodies and uses thereof |
| AU2024223918A1 (en) | 2023-02-17 | 2025-09-11 | Regeneron Pharmaceuticals, Inc. | Induced nk cells responsive to cd3/taa bispecific antibodies |
Family Cites Families (63)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4699880A (en) | 1984-09-25 | 1987-10-13 | Immunomedics, Inc. | Method of producing monoclonal anti-idiotype antibody |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
| US6077835A (en) | 1994-03-23 | 2000-06-20 | Case Western Reserve University | Delivery of compacted nucleic acid to cells |
| KR970029803A (ko) | 1995-11-03 | 1997-06-26 | 김광호 | 반도체 메모리장치의 프리차지 회로 |
| EP0979281B1 (en) | 1997-05-02 | 2005-07-20 | Genentech, Inc. | A method for making multispecific antibodies having heteromultimeric and common components |
| PT1012259E (pt) | 1997-06-04 | 2009-11-06 | Oxford Biomedica Ltd | Vector dirigido a tumor |
| US6355271B1 (en) | 1999-02-03 | 2002-03-12 | Biosante Pharmaceuticals, Inc. | Therapeutic calcium phosphate particles and methods of manufacture and use |
| US6281005B1 (en) | 1999-05-14 | 2001-08-28 | Copernicus Therapeutics, Inc. | Automated nucleic acid compaction device |
| JP2003515323A (ja) | 1999-11-18 | 2003-05-07 | オックスフォード バイオメディカ(ユーケイ)リミテッド | 抗 体 |
| DE10043437A1 (de) | 2000-09-04 | 2002-03-28 | Horst Lindhofer | Verwendung von trifunktionellen bispezifischen und trispezifischen Antikörpern zur Behandlung von malignem Aszites |
| GB0126378D0 (en) | 2001-11-02 | 2002-01-02 | Oxford Biomedica Ltd | Antigen |
| NZ537277A (en) | 2002-07-18 | 2008-04-30 | Crucell Holland Bv | Recombinant production of mixtures of antibodies |
| CA2578131A1 (en) * | 2004-09-10 | 2006-03-23 | Wyeth | Humanized anti-5t4 antibodies and anti-5t4 antibody/calicheamicin conjugates |
| US7741568B2 (en) | 2005-01-13 | 2010-06-22 | The Wiremold Company | Downward facing receptacle assembly for cable raceway |
| KR101374454B1 (ko) | 2005-03-31 | 2014-03-17 | 추가이 세이야쿠 가부시키가이샤 | 회합제어에 의한 폴리펩티드 제조방법 |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| KR101866623B1 (ko) | 2005-11-28 | 2018-07-04 | 젠맵 에이/에스 | 재조합 1가 항체 및 그의 제조 방법 |
| SG170091A1 (en) * | 2006-03-10 | 2011-04-29 | Wyeth Corp | Anti-5t4 antibodies and uses thereof |
| EA015992B1 (ru) | 2006-03-17 | 2012-01-30 | Байоджен Айдек Эмэй Инк. | Стабилизированное антитело и многовалентная антигенсвязывающая молекула на его основе, способы получения и использования вышеназванного стабилизированного антитела |
| DK1999154T3 (da) | 2006-03-24 | 2012-12-03 | Merck Patent Gmbh | Fremstillede heterodimere proteindomæner |
| AT503902B1 (de) | 2006-07-05 | 2008-06-15 | F Star Biotech Forsch & Entw | Verfahren zur manipulation von immunglobulinen |
| EP2626372B1 (en) | 2007-03-29 | 2018-03-21 | Genmab A/S | Bispecific antibodies and methods for production thereof |
| EP2158221B1 (en) | 2007-06-21 | 2018-08-29 | MacroGenics, Inc. | Covalent diabodies and uses thereof |
| US8227577B2 (en) | 2007-12-21 | 2012-07-24 | Hoffman-La Roche Inc. | Bivalent, bispecific antibodies |
| EP3663318A1 (en) | 2008-01-07 | 2020-06-10 | Amgen Inc. | Method for making antibody fc-heterodimeric molecules using electrostatic steering effects |
| WO2010015792A1 (en) | 2008-08-06 | 2010-02-11 | Argenta Discovery Limited | Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors |
| JP5397668B2 (ja) | 2008-09-02 | 2014-01-22 | ソニー株式会社 | 記憶素子および記憶装置 |
| JP5734201B2 (ja) | 2008-12-19 | 2015-06-17 | マクロジェニクス,インコーポレーテッド | 共有結合型ダイアボディ及びその使用 |
| US9067986B2 (en) | 2009-04-27 | 2015-06-30 | Oncomed Pharmaceuticals, Inc. | Method for making heteromultimeric molecules |
| US9493578B2 (en) | 2009-09-02 | 2016-11-15 | Xencor, Inc. | Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens |
| GB0918383D0 (en) | 2009-10-20 | 2009-12-02 | Cancer Rec Tech Ltd | Prognostic,screening and treatment methods and agents for treatment of metastasis and inflammation |
| TWI426920B (zh) | 2010-03-26 | 2014-02-21 | Hoffmann La Roche | 雙專一性、雙價抗-vegf/抗-ang-2抗體 |
| PT2560993T (pt) | 2010-04-20 | 2024-09-16 | Genmab As | Proteínas contendo anticorpo heterodimérico fc e métodos para a produção das mesmas |
| WO2011143545A1 (en) | 2010-05-14 | 2011-11-17 | Rinat Neuroscience Corporation | Heterodimeric proteins and methods for producing and purifying them |
| IL299365A (en) | 2010-05-27 | 2023-02-01 | Genmab As | Monoclonal antibodies against 2HER |
| CN103068846B9 (zh) | 2010-08-24 | 2016-09-28 | 弗·哈夫曼-拉罗切有限公司 | 包含二硫键稳定性Fv片段的双特异性抗体 |
| BR112013002167A2 (pt) | 2010-08-24 | 2016-05-31 | Roche Glycart Ag | anticorpo biespecífico, composição farmacêutica, uso, método de tratamento de um paciente que sofre de câncer e de um paciente que sofre de inflamação |
| CN103429620B (zh) | 2010-11-05 | 2018-03-06 | 酵活有限公司 | 在Fc结构域中具有突变的稳定异源二聚的抗体设计 |
| CN102250246A (zh) | 2011-06-10 | 2011-11-23 | 常州亚当生物技术有限公司 | 抗VEGF/PDGFRβ双特异性抗体及其应用 |
| MX2014003313A (es) * | 2011-09-23 | 2014-07-09 | Amgen Res Munich Gmbh | Moleculas de union biespecificas para 5t4 y cd3. |
| IN2014CN03887A (cg-RX-API-DMAC7.html) | 2011-10-27 | 2015-10-16 | Genmab As | |
| WO2014006217A1 (en) | 2012-07-06 | 2014-01-09 | Genmab B.V. | Dimeric protein with triple mutations |
| WO2014137931A1 (en) | 2013-03-06 | 2014-09-12 | Imaginab, Inc. | Antigen binding constructs to 5t4 |
| KR102813816B1 (ko) | 2013-07-05 | 2025-05-29 | 젠맵 에이/에스 | 인간화 또는 키메라 cd3 항체 |
| WO2015155345A1 (en) * | 2014-04-11 | 2015-10-15 | Medimmune Limited | Antibodies and antibody-drug conjugates |
| WO2016022939A1 (en) * | 2014-08-08 | 2016-02-11 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Human monoclonal antibodies specific for 5t4 and methods of their use |
| MX384198B (es) | 2014-12-19 | 2025-03-14 | Chiome Bioscience Inc | Proteina de fusion que comprende tres dominios de union a 5t4 y cd3. |
| FI3322727T3 (fi) | 2015-07-15 | 2026-03-17 | Genmab As | Humanisoituja tai kimeerisiä CD3-vasta-aineita |
| HK1258306A1 (zh) | 2015-10-29 | 2019-11-08 | F. Hoffmann-La Roche Ag | 具有共同轻链的转基因兔 |
| EP3184547A1 (en) * | 2015-10-29 | 2017-06-28 | F. Hoffmann-La Roche AG | Anti-tpbg antibodies and methods of use |
| KR20180083425A (ko) * | 2015-11-24 | 2018-07-20 | 신톤 바이오파머슈티칼즈 비.브이. | 항-5t4 항체 및 항체-약물 접합체 |
| CN110698559B (zh) * | 2015-12-24 | 2021-11-26 | 凯惠科技发展(上海)有限公司 | 一种tpbg抗体及其制备方法、其偶联物和应用 |
| BR112018071612A2 (pt) * | 2016-04-22 | 2019-02-19 | Alligator Bioscience Ab | polipeptídeos biespecíficos inovadores contra cd137 |
| CN108285487B (zh) | 2017-01-08 | 2021-02-19 | 浙江昭华生物医药有限公司 | 抗5t4抗体-药物偶联物及其应用 |
| EP3595705A1 (en) | 2017-03-15 | 2020-01-22 | Oxford BioMedica (UK) Limited | Method |
| WO2018184558A1 (zh) | 2017-04-05 | 2018-10-11 | 凯惠科技发展(上海)有限公司 | 一种人源化抗tpbg抗体及其制备方法、其偶联物和应用 |
| US11725060B2 (en) | 2017-07-20 | 2023-08-15 | Aptevo Reserch and Development LLC | Antigen binding proteins binding to 5T4 and 4-1BB and related compositions and methods |
| US20220267403A1 (en) | 2017-12-01 | 2022-08-25 | Fred Hutchinson Cancer Research Center | Binding proteins specific for 5t4 and uses thereof |
| CN111787949A (zh) | 2018-02-15 | 2020-10-16 | 宏观基因有限公司 | 变体cd3-结合结构域及其在用于治疗疾病的组合疗法中的用途 |
| MA52152A (fr) | 2018-03-12 | 2021-01-20 | Genmab As | Anticorps |
| US12674001B2 (en) * | 2019-09-12 | 2026-07-07 | Genmab A/S | Method of treating cancer by administering an antibody which binds to 5T4 |
-
2019
- 2019-03-12 MA MA052152A patent/MA52152A/fr unknown
- 2019-03-12 AU AU2019233523A patent/AU2019233523B2/en active Active
- 2019-03-12 SG SG11202008399QA patent/SG11202008399QA/en unknown
- 2019-03-12 CN CN202510716554.XA patent/CN120795158A/zh active Pending
- 2019-03-12 KR KR1020207028911A patent/KR20200130723A/ko not_active Ceased
- 2019-03-12 BR BR112020018490-0A patent/BR112020018490A2/pt unknown
- 2019-03-12 CR CR20200463A patent/CR20200463A/es unknown
- 2019-03-12 CR CR20250348A patent/CR20250348A/es unknown
- 2019-03-12 CR CR20250347A patent/CR20250347A/es unknown
- 2019-03-12 EP EP19710414.4A patent/EP3765493A2/en active Pending
- 2019-03-12 CN CN201980025412.1A patent/CN111971298B/zh active Active
- 2019-03-12 MX MX2020009379A patent/MX2020009379A/es unknown
- 2019-03-12 CA CA3093745A patent/CA3093745A1/en active Pending
- 2019-03-12 JP JP2020548645A patent/JP7209008B2/ja active Active
- 2019-03-12 WO PCT/EP2019/056197 patent/WO2019175198A2/en not_active Ceased
- 2019-03-12 PE PE2020001384A patent/PE20210339A1/es unknown
-
2020
- 2020-03-09 US US16/813,167 patent/US20200277397A1/en not_active Abandoned
- 2020-08-31 IL IL277030A patent/IL277030A/en unknown
- 2020-09-08 SA SA523440623A patent/SA523440623B1/ar unknown
- 2020-09-08 SA SA520420109A patent/SA520420109B1/ar unknown
- 2020-09-08 CL CL2020002326A patent/CL2020002326A1/es unknown
- 2020-09-08 SA SA523440622A patent/SA523440622B1/ar unknown
- 2020-09-09 MX MX2025003351A patent/MX2025003351A/es unknown
- 2020-09-09 MX MX2025003356A patent/MX2025003356A/es unknown
- 2020-09-09 MX MX2025003353A patent/MX2025003353A/es unknown
- 2020-09-09 MX MX2025003350A patent/MX2025003350A/es unknown
- 2020-09-09 MX MX2025003349A patent/MX2025003349A/es unknown
- 2020-09-09 MX MX2025003354A patent/MX2025003354A/es unknown
- 2020-09-11 PH PH12020551447A patent/PH12020551447A1/en unknown
- 2020-10-07 CO CONC2020/0012524A patent/CO2020012524A2/es unknown
- 2020-10-07 EC ECSENADI202063690A patent/ECSP20063690A/es unknown
- 2020-10-22 US US17/077,376 patent/US11008399B2/en active Active
-
2021
- 2021-04-12 US US17/228,023 patent/US11130819B2/en active Active
- 2021-06-21 US US17/353,087 patent/US11970544B2/en active Active
-
2022
- 2022-09-09 JP JP2022143428A patent/JP7447208B2/ja active Active
-
2024
- 2024-02-28 JP JP2024027970A patent/JP7791229B2/ja active Active
- 2024-03-26 US US18/617,483 patent/US20240392032A1/en active Pending
-
2025
- 2025-12-11 JP JP2025245068A patent/JP2026041981A/ja active Pending
-
2026
- 2026-04-07 AU AU2026202570A patent/AU2026202570A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021534779A (ja) | 抗体構築物がプレロードされた凍結保存nk細胞 | |
| JP2020504171A (ja) | 抗PD−1抗体との組み合わせのための抗Tim−3抗体 | |
| WO2020114478A1 (zh) | Cd3抗体及其药物用途 | |
| EP3882276A1 (en) | Bispecific antibody, preparation method therefor and application thereof | |
| JP2018531219A6 (ja) | Pd−l1抗体 | |
| JP2018531219A (ja) | Pd−l1抗体 | |
| JP2023517753A5 (cg-RX-API-DMAC7.html) | ||
| WO2020114479A1 (zh) | 多特异性蛋白分子 | |
| JP2023513200A (ja) | 抗cd3および抗cd123二重特異性抗体およびその使用 | |
| CN112166125B (zh) | 全人源的抗lag-3抗体及其应用 | |
| KR20230074192A (ko) | 인간 cd3 엡실론에 결합하는 신규의 인간 항체 | |
| CN121758618A (zh) | Pd1和vegfr2双结合剂 | |
| CN112771075A (zh) | 结合至cd33和cd3的双特异性抗体构建体的延长施用 | |
| US20230312709A1 (en) | Antibody targeting CD47 and application thereof | |
| CN119095873A (zh) | 用于靶向杀伤GPC3阳性恶性细胞的双特异性GPC3xCD28和GPC3xCD3抗体及其组合 | |
| CN119060184B (zh) | 抗rage抗体及其应用 | |
| WO2024012434A1 (en) | Antibody, antigen-binding fragment thereof, and pharmaceutical use thereof | |
| EP4703384A1 (en) | Bispecific antibody targeting g protein-coupled receptor | |
| US20240376208A1 (en) | Duplexbodies | |
| CN115368457A (zh) | 抗tigit抗体及其用途 | |
| Zettlitz et al. | Humanization of a mouse monoclonal antibody directed against a cell surface-exposed epitope of membrane-associated heat shock protein 70 (Hsp70) | |
| JP2022547135A (ja) | 増強されたプロテインl捕捉動的結合容量を有する二重特異性抗原結合ポリペプチドの精製方法 | |
| CN119371542B (zh) | 抗rage抗体及其应用 | |
| JP7844430B2 (ja) | 抗gprc5d抗体に対する抗イディオタイプ抗体 | |
| US20240376196A1 (en) | Cd112 antibody and use |